CTC
AXSM icon

Central Trust Company’s Axsome Therapeutics AXSM Stock Holding History

Central Trust Company’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-30
Closed -$2K – 1247
2021
Q2 		$2K Sell
30
-40
-57% -$2.4K ﹤0.01% 1141
2021
Q1 		$4K Buy
+70
New +$4.92K ﹤0.01% 1034

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Central Trust Company's AXSM Position: Q3 2021 in Review

Central Trust Company sold out of Axsome Therapeutics (AXSM) in Q3 2021, closing a stake of 30 shares — an estimated $2K sold.

Central Trust Company first reported a position in AXSM in Q1 2021 and held it in 2 quarters. The position peaked at $4K in Q1 2021. 171 funds tracked by Wall St. Rank hold AXSM as of Q3 2021.

  • Central Trust Company reported no remaining Axsome Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Central Trust Company sold 30 Axsome Therapeutics shares in Q3 2021, an estimated $2K.
  • Central Trust Company first reported a position in Axsome Therapeutics in Q1 2021 and held it in 2 quarters.
  • Central Trust Company's Axsome Therapeutics position peaked at $4K in Q1 2021.
  • 171 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2021.

Based on Central Trust Company's 13F filing for Q3 2021, filed 19 Oct 2021.